The APOA1 Knockout HT29 Polyclonal Cells constitute a genetically heterogeneous population of HT29 human colorectal adenocarcinoma cells featuring CRISPR/Cas9-mediated disruption of the APOA1 gene. This polyclonal knockout pool, generated without single-cell cloning, provides a loss-of-function model to interrogate apolipoprotein A-I biology in an intestinal epithelial context. The product is supplied as a viable, proliferating cell population ready for downstream functional assays, suitable for researchers studying lipid metabolism, lipoprotein assembly, and cancer cell signaling without the clonal selection biases inherent in monoclonal derivatives.
HT29 cells, established from a primary colorectal adenocarcinoma of a 44-year-old female, display an epithelial morphology with microvilli and retain the capacity to differentiate into enterocyte-like cells under appropriate culture conditions. This cell line is extensively utilized as a model for intestinal epithelial physiology, drug absorption mechanisms, mucin glycosylation, and colorectal cancer progression. Its ability to form polarized monolayers and express tight junction proteins makes it particularly relevant for investigating barrier function and vectorial cholesterol transport processes that depend on basolateral and apical lipid transporters.
The APOA1 gene encodes the major protein component of high-density lipoprotein (HDL) particles and is indispensable for reverse cholesterol transport. APOA1 accepts cholesterol from peripheral cells through interactions with the ATP-binding cassette transporter ABCA1, and it activates lecithin?Ccholesterol acyltransferase (LCAT) to esterify free cholesterol, driving HDL maturation. This process is transcriptionally regulated by nuclear receptors including PPARA, PPARG, NR1H3 (LXR alpha), NR1H2 (LXR beta), and RXRA, as well as by HNF4A, insulin, dietary lipids, and pro-inflammatory cytokines such as TNF and IL-1B. Downstream, APOA1 function influences the expression and activity of ABCA1, LCAT, SCARB1, CD36, ABCG1, and CETP, and it physically interacts with LCAT, SCARB1, APOA2, APOE, PON1, phospholipids, and cholesterol to orchestrate HDL biogenesis and remodeling.
In the HT29 cellular environment, APOA1 disruption enables dissection of intestinal cholesterol efflux pathways that are critical for maintaining cellular lipid homeostasis and may intersect with colorectal cancer pathophysiology. HT29 cells express key cholesterol transporters and have been shown to assemble nascent HDL particles; therefore, APOA1 ablation constitutes a relevant system to examine how loss of the primary HDL apolipoprotein alters intracellular cholesterol trafficking, lipid raft composition, and downstream signaling cascades that influence proliferation, differentiation, or inflammatory responses in colonic epithelial cells. The model is particularly suited to explore the crosstalk between HDL metabolism and oncogenic pathways in the gastrointestinal tract.
Researchers can employ this polyclonal knockout model in a variety of experimental workflows: quantifying cholesterol efflux to exogenous acceptors, measuring LCAT activation in conditioned media, profiling gene expression changes via RNA-seq, assessing mucin production and barrier integrity, and screening small-molecule modulators of reverse cholesterol transport. Standard characterization assays include Western blotting and RT-qPCR for APOA1, ABCA1, and LCAT expression, immunofluorescence staining for HDL-associated proteins, ELISA-based quantification of secreted APOA1, and flow cytometric analysis of lipid raft markers. Functional studies of cell proliferation, apoptosis, and migration in the absence of APOA1 further inform the role of HDL components in colorectal cancer cell behavior. For additional technical details or batch-specific data, please contact Ascent Research.
